Recent small studies have demonstrated that statins therapy is correlated with improved outcome in patients with chronic heart failure. Methods: We examined the effect of statin therapy on the outcome of 1,000 patients with chronic CHF NYHA IIlb or IV and echocardiographic ejection fraction < 35% enrolled in the placebo arm of the ENABLE study. Statin therapy allocation was not randomized and decided by each investigator, Statin therapy included simvastatin, atrovastatin, pravastati, lovastatin, cerivastatin and fluvastatin in different doses. Results: Statin treatment was related to a 67% reduction in the risk of all cause mortality (p<0.0001, Figure) but was not correlated with re-admisions due to heart failure. In the present cohort statin treatment was an the strongest predictor of outcome and remained an independed predictor in multivariate analysis. 
Conclusions:
Although retrospective, the results of the present study demonstrate a strong correlation between all cause mortality and statin treatment in patients with heart failure. This ovservation requires verification by a large prospective randomized study.
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Length of stay for heart failure hospitalization in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Background: Disability (i.e. loss of ability to perform independently activities of daily living, ADL), cognitive impairment, depression and poor quality of life (QoL) are common in frail heart failure (HF) elderly pts. However, little is known about the impact of recommended treatments -such as Betablockers (BB) -on these conditions. As a consequence, BB are usually underprescribed because their perceived side effects. Aim of the study was to assess the influence of carvedilol treatment on the degree of disability, cognitive impairment, depressive symptoms and QoL in elderly pts using multimensional assessment instruments. Methods: A total of 1126 pts aged >70 yrs (76±5, range 70-93, Males 63%, NYHA III-IV 51.8%) from the observational multicentre study BRING-UP2 (Betablockers in patients with congestive heart failure.Guided use in clinical practice-2) were evaluated. Data were collected at baseline and at 1-year follow-up using VAS questionnaire (eValuation of elderly pAtientS), including: socio-economic factors, ADL score (14-item scale), cognitive function (MMSE, WAIS Digit-Symbol: WDS), depressive symptoms (15-item GDS) and Quality of Life (Minnesota LHFQ). Results: At baseline visit, 375 pts (33%) were already on BB treatment and were excluded from the study, 317 (28.2%) started BB treatment (ST) and 434 (38.8%) were found not eligible to BB (NT), according to Guidelines recommendations. Except for gender (25.2% vs 41.7% males on ST vs NT pts, p<0.01), comorbidity (Charlson index >2 49% vs 62%, p=0.0029) no baseline significant differences were found between the 2 groups in socio-economic variables, depressive symptoms (GDS >6 46.5% vs 47.0% (p--ns), disability (ADL score<ll 42.5% vs 42.6%
